Search Results
Jul 30, 2026, 13:16 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)
https://monteverdelaw.com/case/sanara-medtech-inc/https://monteverdelaw.com/?post_type=case&p=12938&preview=truehttps://monteverdelaw.com/case/patrick-industries-inc/https://monteverdelaw.com/case/psb-holdings-inc/https://monteverdelaw.com/case/xoma-royalty-corporation/
More news about: Monteverde & Associates PC
Jul 16, 2026, 04:00 ET Slone Partners Places Amer Mirza, PhD, as Chief Scientific Officer at Prolynx
Translational Sciences at Septerna, and previously held senior R&D and translational leadership roles at Ascendis Pharma, Gilead Sciences, and XOMA."Dr. Amer Mirza is an accomplished scientific leader whose deep expertise in drug discovery and development and passion for innovation make him
More news about: Slone Partners
Jun 30, 2026, 13:59 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LCI Industries (NYSE: LCII)
https://monteverdelaw.com/case/lci-industries/https://monteverdelaw.com/case/psb-holdings-inc/https://monteverdelaw.com/case/xoma-royalty-corporation/https://monteverdelaw.com/case/globalstar-inc-2/https://monteverdelaw.com/case/calisa-acquisition-corp/https://monteverdelaw.com/?post_type=case&p=12170&preview=true.
More news about: Monteverde & Associates PC
Jun 29, 2026, 13:36 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
https://monteverdelaw.com/case/theravance-biopharma-inc/https://monteverdelaw.com/case/psb-holdings-inc/https://monteverdelaw.com/case/xoma-royalty-corporation/https://monteverdelaw.com/case/globalstar-inc-2/https://monteverdelaw.com/case/calisa-acquisition-corp/
More news about: Monteverde & Associates PC
Jun 24, 2026, 15:36 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Selectis Health, Inc. (OTCMKTS: GBCS)
https://monteverdelaw.com/case/selectis-health-inc/https://monteverdelaw.com/case/psb-holdings-inc/https://monteverdelaw.com/case/xoma-royalty-corporation/https://monteverdelaw.com/case/globalstar-inc-2/https://monteverdelaw.com/case/calisa-acquisition-corp/
More news about: Monteverde & Associates PC
Jun 17, 2026, 13:50 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Olin Corporation (NYSE: OLN)
https://monteverdelaw.com/case/olin-corporation/https://monteverdelaw.com/case/psb-holdings-inc/https://monteverdelaw.com/case/xoma-royalty-corporation/https://monteverdelaw.com/case/globalstar-inc-2/https://monteverdelaw.com/case/calisa-acquisition-corp/https://monteverdelaw.com/?post_type=case&p=12170&preview=true.
More news about: Monteverde & Associates PC
Jun 12, 2026, 11:47 ET Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
click here to learn more about your rights and options.XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder,
More news about: Halper Sadeh LLP
Jun 10, 2026, 13:59 ET SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP
you.XOMA Royalty Corporation (NASDAQ: XOMA) related to its sale to Ligand
More news about: Monteverde & Associates PC
May 14, 2026, 17:25 ET Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder,
More news about: Halper Sadeh LLP
May 08, 2026, 17:57 ET Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
click here to learn more about your rights and options.XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder,
More news about: Halper Sadeh LLP
May 06, 2026, 14:27 ET SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX
you.XOMA Royalty Corporation (NASDAQ: XOMA) related to its sale to Ligand
More news about: Monteverde & Associates PC
May 04, 2026, 14:55 ET Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder,
More news about: Halper Sadeh LLP
Apr 27, 2026, 15:06 ET ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they
More news about: Rowley Law PLLC
Apr 27, 2026, 11:24 ET Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
click here to learn more about your rights and options.XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder,
More news about: Halper Sadeh LLP
Apr 27, 2026, 10:00 ET Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders
obligation to you.XOMA stockholders will receive $39.00 per share in cash, representing a total equity value of approximately $739 million. The transaction includes an additional contingent value right for XOMA stockholders related to ongoing litigation proceeds.XOMA insiders will receive
More news about: Ademi LLP
Jan 23, 2026, 11:01 ET Halper Sadeh LLC Encourages DHIL, GBIO, CTGO Shareholders to Contact the Firm to Discuss Their Rights
click here to learn more about your rights and options.Generation Bio Co. (NASDAQ: GBIO)'s sale to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments
More news about: Halper Sadeh LLP
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 13, 2026, 01:52 ET Halper Sadeh LLC Encourages CTGO, GBIO, CDE Shareholders to Contact the Firm to Discuss Their Rights
click here to learn more about your legal rights and options.Generation Bio Co. (NASDAQ: GBIO)'s sale to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments
More news about: Halper Sadeh LLP
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Dec 16, 2025, 11:21 ET Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights
click here to learn more about your legal rights and options.Generation Bio Co. (NASDAQ: GBIO)'s sale to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments
More news about: Halper Sadeh LLP
Dec 15, 2025, 20:21 ET Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders
investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XOMA Royalty Corporation.
More news about: Ademi LLP
Dec 02, 2025, 18:48 ET Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Doberstein, Ph.D.Former Chief Scientific Officer and Chief R&D Officer at Nektar Therapeutics, with prior senior roles at XOMA, Five Prime Therapeutics and XencorMore than two decades of experience designing and running clinical programs, including in complex therapeutic
More news about: Lynx1 Capital Management LP
Oct 20, 2025, 12:58 ET Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement
/PRNewswire/ --The Ademi Firm is investigating Lava (Nasdaq: LVTX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty.
More news about: Ademi LLP